In the world economic growth, the Cephalosporin Industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Cephalosporin market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2019, SMI analysts believe that in the next few years, Cephalosporin market size will be further expanded, we expect that by 2024, The market size of the Cephalosporin will reach XXX million $.
The cephalosporins are a class of β-lactam antibiotics originally derived from the fungus Acremonium. Cephalosporins are used for the treatment of infections caused by susceptible bacteria such as bone infections, ear infections, skin infections, upper respiratory tract infections, and urinary tract infections. There are different types of cephalosporins that include, first-generation cephalosporins, second-generation cephalosporins, third-generation cephalosporins, fourth-generation cephalosporins, and fifth-generation cephalosporins.
Long half-life of third-generation cephalosporins is expected to propel growth of the global cephalosporins market over the forecast period. For instance, ceftriaxone, a third-generation cephalosporin, has a long half-life which allows for once-daily dosing and is used for the treatment of gonorrhea, pelvic inflammatory disease, and epididymo-orchitis. Moreover, increasing the incidence of gonorrhea is also expected to aid in growth of the market. For instance, according to the Centers for Disease Control and Prevention, the rate of reported gonorrhea cases increased 5.0%, and increased 82.6% during 2017–2018 and a total of 583,405 cases of gonorrhea were reported in the U.S. in 2018.
Increasing the prevalence of otitis media is expected to boost growth of the global cephalosporins market. For instance, according to the study, “Prevalence of chronic suppurative otitis media in schoolgoing children”, published in 2018, in the Indian Journal of Otology, the prevalence of chronic suppurative otitis media in urban school children was 2.32%, while for rural children, it was 5.11%.
However, the use of cephalosporins can lead to some side effects such as abdominal pain, diarrhea, dyspepsia, headache, gastritis, and nausea vomiting, and transient liver problems, which are expected to hinder growth of the global cephalosporins market to some extent.
Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in March 2020, ADVANZ PHARMA Corp. Limited, a global pharmaceutical company, entered into an arrangement to acquire outstanding shares of Correvio Pharma Corp., specialty pharmaceutical company and developer of Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia.
Major players in the market are also focused on conducting clinical trials to expand their product portfolio. For instance, in February 2020, Allecra Therapeutics, a France-based pharmaceutical company, announced that its Exblifep (cefepime-enmetazobactam), a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and the fourth-generation cephalosporin cefepime, achieved primary endpoints in a clinical trial for complicated urinary tract infections (cUTI).
Key Takeaways:
- Increasing prevalence of otitis media to augment growth of the global cephalosporins market
- Major players operating in the global cephalosporins market include, Union Chempharma, NCPC, Qilu Antibiotics, Lupin Pharmaceuticals, Hospira, Dhanuka Laboratories, Fukang, Dongying Pharmaceutical, Alkem, SALUBRIS, LIVZON, Hetero Drugs, CSPC, Teva Pharmaceuticals, ADVANZ PHARMA Corp. Limited, Orchid Pharma, Taj Pharmaceuticals, Covalent Laboratories, United Laboratories, Aurobindo, Wockhardt, LKPC, HPGC, and Huafangpharm
This Report covers the manufacturers' data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.
Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. It also covers different industries ' client's information, which is very important for the manufacturers. If you need more information, please contact SMI
Section 1: Definition
Section (2 3): Manufacturer Detail
Union Chempharma
NCPC
Qilu Antibiotics
Lupin Pharmaceuticals
Hospira
Dhanuka Laboratories
Fukang
Dongying Pharmaceutical
Alkem
SALUBRIS
LIVZON
Hetero Drugs
CSPC
TEVA
Orchid Pharma
Taj Pharmaceuticals
Covalent Laboratories
United Laboratories
Aurobindo
Wockhardt
LKPC
HPGC
Huafangpharm
Section 4: Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)
Section (5 6 7): Segmentation
Product Type Segmentation:
First Generation
Second Generation
Third Generation
Fourth Generation
Industry Segmentation:
Oral
Injection
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2019-2024)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
Request Discount 
Inquire Before Buy
